Starling Oncology (STLNW) EBIT (2020 - 2026)

Starling Oncology (STLNW) has reported EBIT for 7 consecutive years, with -$4.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 58.83% year-over-year to -$4.6 million; the trailing twelve-month figure through Jun 2026 stood at -$26.1 million (up 44.38% YoY), and the FY2025 full-year result was -$36.1 million, up 39.98% from the prior year.
• EBIT grew to -$4.6 million in Q2 2026 per STLNW's latest filing, from -$6.5 million in the prior quarter.
• Across five years, EBIT topped out at -$4.6 million in Q2 2026 and bottomed at -$32.9 million in Q1 2023.
• Historically, EBIT has averaged -$14.8 million across 5 years, with a median of -$14.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: EBIT plunged 1540.14% in 2022, then soared 58.83% in 2026.
• Over 5 years, EBIT stood at -$25.1 million in 2022, then surged by 39.04% to -$15.3 million in 2023, then climbed by 21.97% to -$11.9 million in 2024, then soared by 42.1% to -$6.9 million in 2025, then soared by 33.17% to -$4.6 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$4.6 million, -$6.5 million, and -$6.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.